ProQR Therapeutics (PRQR) Receivables - Net (2022 - 2026)

ProQR Therapeutics (PRQR) posted Receivables - Net of $5.2 million for Q1 2026, down 34.86% sequentially from $7.9 million in Q4 2025.

ProQR Therapeutics (PRQR) Receivables - Net (2022 - 2026) Analysis & Trends

ProQR Therapeutics has reported Receivables - Net for 4 years, with the latest figure at $5.2 million in Q1 2026.

Quarterly Receivables - Net changed N/A year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.2 million (changed N/A YoY) and the FY2025 annual result came in at $7.9 million, up 97.69% from the prior year.
Receivables - Net retreated to $5.2 million in Q1 2026 per PRQR's latest filing, from $7.9 million in the prior quarter.
Over five years, Receivables - Net peaked at $57.4 million in Q4 2022 and troughed at $4.0 million in Q4 2024.
A 4-year average of $18.6 million and a median of $6.5 million in 2026 frame the typical range for Receivables - Net.
The widest YoY moves for Receivables - Net: up 97.69% in 2025, down 97.69% in 2025.
Over 4 years, Receivables - Net stood at $57.4 million in 2022, then tumbled by 93.02% to $4.0 million in 2024, then surged by 97.69% to $7.9 million in 2025, then sank by 34.86% to $5.2 million in 2026.
According to Business Quant data, Receivables - Net over the past three periods registered $5.2 million, $7.9 million, and $4.0 million for Q1 2026, Q4 2025, and Q4 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	ProQR Therapeutics	206.80 Mn	111.86 Mn	-

Download Data